SynthesisThe Indian journal of medical research2026
Immunotherapeutic effect of MIP vaccine along with multidrug therapy (MDT) in leprosy: A systematic review and meta-analysis.
Synthesis in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Leprosy is a neglected tropical disease caused by Mycobacterium leprae often resulting in nerve damage, numbness, disfiguring lesions, and disability. India accounts for ∼52% of the world's new leprosy patients. Immunotherapy has been reported to achieve faster bacterial clearance in multi-bacillary (MB) leprosy patients. We conducted this systematic review to synthesise the global evidence available for the efficacy and safety of the MIP vaccine (Mycobacterium indicus pranii), previously known as Mw, as an immunotherapeutic agent along with standard chemotherapy, on the treatment outcomes in patients with multi-bacillary (MB) and pauci-bacillary (PB) leprosy. Methods Three bibliographic databases namely, PubMed, Embase, and Cochrane Library were used for search of articles apart from four clinical trial registries, Google Scholar, and the Google search engine. Articles published between 1980 to 2023 reporting the efficacy of the MIP vaccine for immunotherapy along with standard chemotherapy in leprosy patients were included. Methodological bias was assessed using the RoB2 and ROBIN-I tool. Meta-analysis was carried out from four RCTs and three non-RCTs for the outcomes clinical score and bacterial index following 12 and 24 mo of treatment using the Review Manager 5.4.1 (RevMan). Results The pooled analysis of four RCTs with 12 and 24 mo of follow up showed a significant reduction in clinical scores with mean difference of -1.35 [95% confidence interval (CI): -2.12 to -0.57] and -2.62 (95% CI: -4.28 to -0.96) respectively, while the analysis of three non-RCTs showed a mean difference of -2.97 (95% CI: -4.00 to -1.94) and -3.10 (95% CI: -3.84 to -2.37) at 12 and 24 mo respectively. Subgroup analysis showed a significant reduction in clinical scores and bacterial index among borderline lepromatous (BL) and lepromatous leprosy (LL) types of leprosy. The vaccine was reported to be safe and well-tolerated. Interpretation and conclusions This systematic review and meta-analysis confirms the clinical efficacy of the MIP as an immunotherapeutic vaccine in leprosy patients for rapid bacterial clearance and overall clinical improvement when used as an adjunct to chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.